Analysts expect that CareDx Inc (NASDAQ:CDNA) will report ($0.03) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for CareDx’s earnings. CareDx posted earnings per share of ($0.15) during the same quarter last year, which indicates a positive year over year growth rate of 80%. The company is scheduled to issue its next earnings results on Thursday, November 8th.

Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for CareDx.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings data on Thursday, August 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.03. CareDx had a negative return on equity of 108.99% and a negative net margin of 121.92%. The company had revenue of $17.82 million during the quarter, compared to analysts’ expectations of $15.30 million.

A number of equities analysts recently issued reports on CDNA shares. Zacks Investment Research upgraded CareDx from a “sell” rating to a “hold” rating in a report on Monday, August 27th. Piper Jaffray Companies boosted their price objective on CareDx to $42.00 in a report on Wednesday, September 5th. HC Wainwright set a $17.00 price objective on CareDx and gave the company a “hold” rating in a report on Friday, August 10th. Finally, TheStreet cut CareDx from a “c-” rating to a “d” rating in a report on Monday, June 11th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and two have given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $18.90.

CDNA traded up $0.09 during trading hours on Tuesday, reaching $25.95. 2,014,577 shares of the company’s stock traded hands, compared to its average volume of 731,871. CareDx has a 52-week low of $2.81 and a 52-week high of $27.55. The company has a quick ratio of 1.83, a current ratio of 2.16 and a debt-to-equity ratio of 0.46. The stock has a market cap of $943.18 million, a P/E ratio of -33.70 and a beta of 0.94.

In other news, COO Mitchell J. Nelles sold 39,649 shares of the business’s stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $12.48, for a total value of $494,819.52. Following the completion of the transaction, the chief operating officer now directly owns 89,639 shares of the company’s stock, valued at approximately $1,118,694.72. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Sasha King sold 9,458 shares of the business’s stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $14.03, for a total value of $132,695.74. Following the completion of the transaction, the insider now directly owns 71,792 shares of the company’s stock, valued at $1,007,241.76. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 92,962 shares of company stock valued at $1,594,372. 3.40% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CDNA. BlackRock Inc. raised its position in shares of CareDx by 3,947.9% in the 2nd quarter. BlackRock Inc. now owns 2,261,305 shares of the company’s stock worth $27,677,000 after acquiring an additional 2,205,441 shares in the last quarter. Fred Alger Management Inc. raised its position in shares of CareDx by 61.4% in the 2nd quarter. Fred Alger Management Inc. now owns 3,262,790 shares of the company’s stock worth $39,937,000 after acquiring an additional 1,241,668 shares in the last quarter. Polar Asset Management Partners Inc. bought a new position in shares of CareDx in the 1st quarter worth $6,860,000. Next Century Growth Investors LLC raised its position in shares of CareDx by 101.1% in the 1st quarter. Next Century Growth Investors LLC now owns 1,576,858 shares of the company’s stock worth $12,567,000 after acquiring an additional 792,629 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of CareDx by 737.0% in the 2nd quarter. Northern Trust Corp now owns 369,484 shares of the company’s stock worth $4,523,000 after acquiring an additional 325,341 shares in the last quarter. 72.84% of the stock is owned by hedge funds and other institutional investors.

About CareDx

CareDx, Inc, a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics.

Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Get a free copy of the Zacks research report on CareDx (CDNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.